Patients
From July 2018 to September 2020, 16 pediatric patients with relapsed and refractory Wilms’ tumor who received doxorubicin hydrochloride liposome plus irinotecan regimen treated at Sun Yat-Sen University Cancer Center were collected and included in the analysis. The inclusion criteria include the following: (1) Patients with relapsed and refractory Wilms’ tumor aged ≤ 18 years; (2) Doxorubicin Hydrochloride Liposome plus irinotecan chemotherapy regimen; (3) The presence of evaluable target lesions; (4) Complete clinical data. Exclusion criteria was that Patients who had previously received chemotherapy with doxorubicin-containing liposomes or irinotecan regimens.
This study was approved by the Sun Yat-Sen University Cancer Center Ethics Committee.